PEAT Act of 2026
- Bill Number
- H.R. 8630
- Origin Chamber
- House
- Congress
- 119th Congress, Session 2
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2026-04-30: Referred to the House Committee on Energy and Commerce.
- Last Updated
- 2026-06-30T08:06:05Z
AI-Generated Summary
Purpose
The Protecting Equal Access to Thyroid Act of 2026 (PEAT Act) aims to clarify the definition of a "biological product" under federal law. It prevents certain biologics—likely including synthetic thyroid hormone treatments—from being automatically classified as biological products solely due to containing a clinically inactive protein (a protein that has no therapeutic effect). This ensures equal access to treatments by avoiding stricter regulatory requirements associated with biological products.
Key Provisions
- Amends Section 351(i)(1) of the Public Health Service Act (42 U.S.C. 262(i)(1)):
- Redesignates the existing definition of "biological product" as subparagraph (A).
- Adds new subparagraph (B): Prohibits treating a biologic as a biological product based solely on the presence of a clinically inactive protein component.
- Includes a minor technical correction to fix punctuation in the definition (adding a comma after "protein").
Significant Changes to Existing Law
- Narrows the scope of "biological product": Previously, the presence of any protein could trigger classification as a biological product, subjecting it to more rigorous FDA approval processes (e.g., via Biologics License Applications instead of simpler drug approvals).
- Provides explicit exclusion for biologics where proteins are inactive, promoting regulatory clarity without altering core definitions.
Potential Impacts
- Government agencies (FDA): Reduces administrative burden by preventing reclassification of certain products; streamlines approvals for non-complex biologics like thyroid hormones.
- Citizens: Improves access to affordable thyroid treatments (e.g., levothyroxine), potentially lowering costs and shortages by keeping them under less stringent "drug" pathways.
- No direct impact on international relations.
Main Stakeholders Affected
- Patients with thyroid conditions (primary beneficiaries for easier access).
- Pharmaceutical manufacturers of synthetic thyroid drugs (avoids costly biologic licensing).
- FDA and healthcare providers (simplified regulation and supply chain).
Notable Legal, Constitutional, or Political Implications
- Legal: Enhances predictability in FDA classifications, reducing litigation risk over product status; aligns with existing statutory definitions without expanding agency authority.
- Constitutional: None apparent; standard congressional amendment of public health law.
- Political: Bipartisan sponsorship (Reps. Rulli and Harshbarger); addresses niche healthcare access issues, potentially influencing drug pricing debates. Referred to House Committee on Energy and Commerce for further review.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Rep. Rulli, Michael A. [R-OH-6]
Cosponsors (9)
Rep. Harshbarger, Diana [R-TN-1], Rep. Luttrell, Morgan [R-TX-8], Rep. Babin, Brian [R-TX-36], Rep. Kennedy, Mike [R-UT-3], Rep. Carter, John R. [R-TX-31], Rep. Hamadeh, Abraham J. [R-AZ-8], Rep. Weber, Randy K. Sr. [R-TX-14], Rep. Nehls, Troy E. [R-TX-22], Rep. McCaul, Michael T. [R-TX-10]
Recent Actions
- 2026-04-30: Referred to the House Committee on Energy and Commerce.
- 2026-04-30: Introduced in House
- 2026-04-30: Introduced in House
Bill Versions
- Protecting Equal Access to Thyroid Act of 2026 — issued 2026-04-30 — PDF (2 pages)